呼出一氧化氮>300 ppb的患者发生呼吸衰竭及随后对度普利尤单抗的反应
Respiratory failure in a patient with exhaled nitric oxide >300 ppb and subsequent response to dupilumab.
作者信息
Crisp Howard
机构信息
North Texas Allergy and Asthma Associates and Division of Allergy/Immunology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA.
出版信息
Proc (Bayl Univ Med Cent). 2024 Aug 28;38(1):81-84. doi: 10.1080/08998280.2024.2395213. eCollection 2025.
Abstract
Multiple biologic agents are approved for the treatment of severe persistent asthma not controlled by inhaled corticosteroid/beta-agonist therapy. Appropriate phenotyping can aid in picking the right biologic for the right patient. Here is a unique case of a patient with severe asthma and respiratory arrest, with fraction of exhaled nitric oxide >300 ppb whose asthma became completely controlled with dupilumab.
摘要
多种生物制剂已被批准用于治疗经吸入性糖皮质激素/β受体激动剂治疗后仍无法控制的重度持续性哮喘。适当的表型分析有助于为合适的患者选择合适的生物制剂。以下是一个独特的病例，一名患有重度哮喘和呼吸骤停的患者，其呼出一氧化氮分数>300 ppb，使用度普利尤单抗后哮喘得到完全控制。
相似文献
1
Respiratory failure in a patient with exhaled nitric oxide >300 ppb and subsequent response to dupilumab.呼出一氧化氮>300 ppb的患者发生呼吸衰竭及随后对度普利尤单抗的反应
Proc (Bayl Univ Med Cent). 2024 Aug 28;38(1):81-84. doi: 10.1080/08998280.2024.2395213. eCollection 2025.
2
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial.度普利尤单抗对2型哮喘患者呼出气一氧化氮、黏液栓及功能性呼吸成像的影响（VESTIGE）：一项随机、双盲、安慰剂对照的4期试验
Lancet Respir Med. 2025 Mar;13(3):208-220. doi: 10.1016/S2213-2600(24)00362-X. Epub 2025 Feb 10.
3
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.血液嗜酸性粒细胞和呼出气一氧化氮分数是儿童哮喘的预后和预测生物标志物。
J Allergy Clin Immunol. 2024 Jul;154(1):101-110. doi: 10.1016/j.jaci.2023.09.044. Epub 2024 Jan 23.
4
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南（2024年版）]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
5
Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma.在患有严重嗜酸性粒细胞性哮喘的成年真实世界队列中，使用呼出一氧化氮（FeNO）预测抗白细胞介素-5（IL-5）和白细胞介素-5受体（IL-5R）生物制剂的疗效。
J Asthma. 2023 Jun;60(6):1162-1170. doi: 10.1080/02770903.2022.2136526. Epub 2022 Nov 15.
6
Prediction of Clinical Response to Dupilumab in Patients with Severe Asthma Using Fractional Exhaled Nitric Oxide Combined with Pulmonary Function Testing.使用呼出气一氧化氮分数与肺功能测试预测重度哮喘患者对度普利尤单抗的临床应答。
Int Arch Allergy Immunol. 2024;185(9):856-864. doi: 10.1159/000538542. Epub 2024 Apr 30.
7
[Mexican consensus on fractional exhaled nitric oxide (FeNO) in asthma 2020].[2020年墨西哥哮喘患者呼出一氧化氮分数（FeNO）共识]
Rev Alerg Mex. 2020;67 Suppl 2:S1-S25. doi: 10.29262/ram.v67i0.760.
8
Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study.度普利尤单抗治疗前重度哮喘患者的真实世界特征：ProVENT研究
Respiration. 2024;103(1):10-21. doi: 10.1159/000535390. Epub 2023 Dec 12.
9
Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial.在家中使用呼出气一氧化氮测定评估持续性哮喘患者吸入皮质激素的剂量反应：FENOtype 试验。
Chest. 2012 Dec;142(6):1553-1561. doi: 10.1378/chest.12-1310.
10
Relationship between fraction of exhaled nitric oxide and peripheral eosinophilia in asthma.呼出气一氧化氮分数与哮喘外周血嗜酸性粒细胞的关系。
Ann Med. 2024 Dec;56(1):2382377. doi: 10.1080/07853890.2024.2382377. Epub 2024 Jul 25.
本文引用的文献
1
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.基线呼出气一氧化氮水平可独立预测中重度哮喘患者对度普利尤单抗的反应。
J Allergy Clin Immunol Pract. 2023 Apr;11(4):1213-1220.e2. doi: 10.1016/j.jaip.2022.11.043. Epub 2022 Dec 16.
2
FeNO in Asthma.哮喘中的呼出气一氧化氮
Semin Respir Crit Care Med. 2022 Oct;43(5):635-645. doi: 10.1055/s-0042-1743290. Epub 2022 Mar 4.
3
Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion.成人严重哮喘的生物药物治疗管理：文献综述和国际专家意见。
J Allergy Clin Immunol Pract. 2022 Feb;10(2):422-432. doi: 10.1016/j.jaip.2021.10.059. Epub 2021 Nov 8.
4
Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial.短期皮下过敏免疫疗法和度普利尤单抗在过敏性鼻炎中耐受性良好：一项随机试验。
J Asthma Allergy. 2021 Aug 16;14:1045-1063. doi: 10.2147/JAA.S318892. eCollection 2021.
5
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma.基线患者特征对 2 型哮喘患者dupilumab 疗效的影响。
Eur Respir J. 2021 Oct 7;58(4). doi: 10.1183/13993003.04605-2020. Print 2021 Oct.
6
High fractional exhaled nitric oxide levels in asthma patients: Does size matter?哮喘患者呼出气一氧化氮分数高：大小重要吗？
Pediatr Pulmonol. 2021 Jun;56(6):1449-1454. doi: 10.1002/ppul.25333. Epub 2021 Mar 17.
7
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation.理解 2 型炎症致不可控持续性哮喘治疗中的关键问题。
Eur Respir J. 2021 Aug 5;58(2). doi: 10.1183/13993003.03393-2020. Print 2021 Aug.
8
Allergen immunotherapy and biologics in respiratory allergy: friends or foes?变应原免疫治疗和呼吸过敏中的生物制剂：是敌是友？
Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):16-23. doi: 10.1097/ACI.0000000000000707.
9
The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma.未选择的严重哮喘患者人群中 2 型炎症亚型的流行情况。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1267-1275. doi: 10.1016/j.jaip.2020.09.051. Epub 2020 Oct 8.
10
The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment.变应原免疫疗法在逐步减少哮喘治疗中的潜在作用
J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):640-648. doi: 10.1016/j.jaip.2016.11.024. Epub 2016 Dec 30.
Zotero 插件